Skip to Main Content

Paper Details

Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors.
Eur Urol
95
2020
Ipilimumab, Metastatic Castration-resistant Prostate Cancer, PARTICIPANTS, PATIENT, bone metastases, docetaxel, ipilimumab, mCRPC, men, metastatic castrate-resistant prostate cancer, patients
Author NameAffiliation
Tomasz M BeerOregon Health & Science University Knight Cancer Institute
Howard I ScherMemorial Sloan-Kettering Cancer Center, USA Weill-Cornell Medical College
Neeraj AgarwalHuntsman Cancer Institute, University of Utah
Andries M BergmanThe Netherlands Cancer Institute and Antoni van Leeuwenhoek Hospital
  • 1 - 4

Datasets

Release 1.2